UNSPSC 51182428: Denosumab

This classification denotes a monoclonal antibody with the molecular formula C6404H9912N1724O2004S50, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EQZ6YO2HI, more generally known as denosumab. European Medicines Agency schedules denosumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29173. The term DENOSUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. Most nations schedule Denosumab under HS 30021020 and SITC 54163.

SMILES:. As of Q4 2014, DENOSUMAB remains the US FDA Preferred Term for this commodity.. Denosumab bears US NLM identifiers UMLS ID C1690432 and NCI Concept Code C61313.

UNSPSC 51182428 Denosumab, a Commodity code, covers the procurement of this monoclonal antibody pharmaceutical used primarily in the treatment of osteoporosis, bone loss in cancer patients, and giant cell tumors of bone. State and local governments purchase denosumab through pharmacy benefit managers, direct pharmaceutical wholesalers, and group purchasing organizations (GPOs) to stock hospital formularies, outpatient clinics, and health department specialty-care programs. The drug is typically procured as a pre-filled syringe or vial in standard dosing strengths, often through standing orders tied to patient volume forecasts and clinical protocols. Issuing bodies include state health departments, county hospital systems, municipal health clinics, and independent school district health services that maintain on-site nursing programs.

The source contains no recent state and local contract opportunities tagged to this code. Without posted RFP, RFQ, IFB, or ITB records, no geographic concentration, representative solicitations, or issuing-body activity patterns can be identified from available procurement data.